These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 16129526

  • 1. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
    Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L.
    Vaccine; 2006 Jan 16; 24(3):254-62. PubMed ID: 16129526
    [Abstract] [Full Text] [Related]

  • 2. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.
    Burt D, Mallett C, Plante M, Zimmermann J, Torossian K, Fries L.
    Expert Rev Vaccines; 2011 Mar 16; 10(3):365-75. PubMed ID: 21434804
    [Abstract] [Full Text] [Related]

  • 3. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 4. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z.
    Vaccine; 2004 Jun 30; 22(20):2566-77. PubMed ID: 15193382
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults.
    Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, Mallett CP, Lowell GH, Fries L.
    Vaccine; 2006 Mar 06; 24(10):1601-8. PubMed ID: 16303215
    [Abstract] [Full Text] [Related]

  • 6. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.
    Vaccine; 2006 May 01; 24(18):3990-4006. PubMed ID: 16516356
    [Abstract] [Full Text] [Related]

  • 7. Local immune responses following nasal delivery of an adjuvanted influenza vaccine.
    Scheerlinck JP, Gekas S, Yen HH, Edwards S, Pearse M, Coulter A, Sutton P.
    Vaccine; 2006 May 01; 24(18):3929-36. PubMed ID: 16540213
    [Abstract] [Full Text] [Related]

  • 8. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.
    Bakke H, Samdal HH, Holst J, Oftung F, Haugen IL, Kristoffersen AC, Haugan A, Janakova L, Korsvold GE, Krogh G, Andersen EA, Djupesland P, Holand T, Rappuoli R, Haneberg B.
    Scand J Immunol; 2006 Mar 01; 63(3):223-31. PubMed ID: 16499576
    [Abstract] [Full Text] [Related]

  • 9. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, Morag A, Zakay-Rones Z.
    J Med Virol; 2001 Sep 01; 65(1):178-84. PubMed ID: 11505461
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.
    Vaccine; 2010 Feb 17; 28(7):1740-5. PubMed ID: 20034605
    [Abstract] [Full Text] [Related]

  • 11. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L.
    Vaccine; 2011 Feb 24; 29(10):1921-8. PubMed ID: 21219987
    [Abstract] [Full Text] [Related]

  • 12. Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs.
    Nishino M, Mizuno D, Kimoto T, Shinahara W, Fukuta A, Takei T, Sumida K, Kitamura S, Shiota H, Kido H.
    Vaccine; 2009 Sep 18; 27(41):5620-7. PubMed ID: 19647064
    [Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens.
    Stanberry LR, Simon JK, Johnson C, Robinson PL, Morry J, Flack MR, Gracon S, Myc A, Hamouda T, Baker JR.
    Vaccine; 2012 Jan 05; 30(2):307-16. PubMed ID: 22079079
    [Abstract] [Full Text] [Related]

  • 14. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness.
    Bizanov G, Janakova L, Knapstad SE, Karlstad T, Bakke H, Haugen IL, Haugan A, Samdal HH, Haneberg B.
    Scand J Immunol; 2005 Jun 05; 61(6):503-10. PubMed ID: 15963044
    [Abstract] [Full Text] [Related]

  • 15. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).
    Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, Ozer K, Tussey L, Shaw A.
    Vaccine; 2011 Jul 12; 29(31):4897-902. PubMed ID: 21596084
    [Abstract] [Full Text] [Related]

  • 16. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I.
    J Infect Dis; 2008 Sep 01; 198(5):642-9. PubMed ID: 18576945
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.
    Clin Infect Dis; 2009 Apr 15; 48(8):1087-95. PubMed ID: 19281330
    [Abstract] [Full Text] [Related]

  • 18. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.
    Huang J, Garmise RJ, Crowder TM, Mar K, Hwang CR, Hickey AJ, Mikszta JA, Sullivan VJ.
    Vaccine; 2004 Dec 21; 23(6):794-801. PubMed ID: 15542204
    [Abstract] [Full Text] [Related]

  • 19. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.
    Bracci L, Canini I, Puzelli S, Sestili P, Venditti M, Spada M, Donatelli I, Belardelli F, Proietti E.
    Vaccine; 2005 Apr 27; 23(23):2994-3004. PubMed ID: 15811645
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
    Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW.
    Vaccine; 2004 Aug 13; 22(23-24):3136-43. PubMed ID: 15297066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.